Myasthenia Gravis (pronounced My-as-theen-ee-a Grav-us) comes from the Greek and Latin words meaning “grave muscular weakness.” The most common form of MG is a chronic autoimmune neuromuscular disorder that is characterized by fluctuating weakness of the voluntary muscle groups. The prevalence of MG in the United States is estimated to be about 20/100,000 population. However, MG is probably under diagnosed and the prevalence may be higher. Myasthenia Gravis occurs in all races, both genders, and at any age. MG is not thought to be directly inherited nor is it contagious. It does occasionally occur in more than one member of the same family.

The voluntary muscles of the entire body are controlled by nerve impulses that arise in the brain. These nerve impulses travel down the nerves to the place where the nerves meet the muscle fibers. Nerve fibers do not actually connect with muscle fibers. There is a space between the nerve ending and muscle fiber; this space is called neuro-muscular junction.

When the nerve impulse originating in the brain arrives at the nerve ending, it releases a chemical called acetylcholine. Acetylcholine travels across the space to the muscle fiber side of the neuromuscular junction where it attaches to many receptor sites. The muscle contracts when enough of the receptor sites have been activated by the acetylcholine. In MG, there can be as much as an 80% reduction in the number of these receptor sites. The reduction in the number of receptor sites is caused by an antibody that destroys or blocks the receptor site.


Antibodies are proteins that play an important role in the immune system. They are normally directed at foreign proteins called antigens that attack the body. Such foreign proteins include bacteria and viruses. Antibodies help the body to protect itself from these foreign proteins. For reasons not well understood, the immune system of the person with MG makes antibodies against the receptor sites of the neuromuscular junction. Abnormal antibodies can be measured in the blood of many people with MG. The antibodies destroy the receptor sites more rapidly than the body can replace them. Muscle weakness occurs when acetylcholine cannot activate enough receptor sites at the neuromuscular junction.

Test & Diagnostic methods:

In addition to a complete medical and neurological evaluation, a number of tests may be used to establish a diagnosis of MG. A characteristic of MG is that patients have weakness that comes on with activity and improves following rest. To examine for weakness with activity, a clinician might have a patient do a sustained task, such as looking upwards (which induces the eyelids to remain elevated) to see if the eyelids start to droop (referred to clinically as ptosis) when the eyelids are open for several minutes. To test for recovery of strength after rest, a clinician may examine muscle strength and then have the patient suspected to have MG rest or rest a part of the body and then retest muscle strength after rest to see if strength improves.


For example if a person who is suspected to have MG has droopy eyelids, the physician might have the patient lay down with his/her eyes closed for several minutes, perhaps with a cool pack over the eyelids, to see if eyelid function improves after rest.


A diagnosis can be confirmed in several ways, including the following:

Acetylcholine Receptor Antibody— a blood test for the abnormal antibodies can be performed to see if they are present. Approximately 85% of MG patients have this antibody and, when detected with an elevated concentration the AChR antibody test is strongly indicative of MG.

Anti-MuSK Antibody testing— a blood test for the remaining 15% of MG patients who have tested negative for the acetylcholine antibody. These patients have seronegative (SN) MG. About 40-70% of patients with SNMG test positive for the anti-MuSK antibody. The remaining patients have unidentified antibodies causing their MG.

OfficeTests—Sleep, Ice Pack and Edrophonium tests are examinations performed by specialists to evaluate an improvement in strength that may be consistent with MG.

Electromyography— (EMG) studies can provide support for the diagnosis of MG when characteristic patterns are present. Repetitive Nerve Stimulation is used to check for a pattern of response that is characteristic of MG.

Single Fiber EMG— studies can provide support for the diagnosis of MG when characteristic patterns are present. The single fiber EMG and AChR antibody test are primary tests used to confirm a clinical diagnosis of MG.

Treatment for MG

There is no known cure for MG, but there are effective treatments available. Common treatments include medications, thymectomy and plasmapheresis. Spontaneous improvement and even remission may occur without specific therapy.

Medications are most frequently used in treatment. Anticholinesterase  agents (e.g.,Mestinon”) allow  acetylcholine  to  remain at the  neuromuscular  junction  longer than  usual so that  more receptor  sites  can  be  activated.  Corticosteroids  (e.g., prednisone)  and  immunosuppressant agents (e.g.,lmuran”) may be used to suppress the abnormal action of the immune system that occurs in MG. Intravenous immunoglobulins (IVlg) are sometimes used to affect the function or production of the abnormal antibodies also.

Treatment  Summary

  • No known cure for MG
  • Effective treatments allow many with MG to lead full lives
  • Treatment goals are individualized

Thymectomy   (surgical  removal  of  the  thymus  gland)  is  another  treatment   used  in  some patients. The thymus gland lies behind the breastbone and is an important part of the immune system. When there is a tumor of the thymus gland (in 10-15% of patients with MG), it is always removed because of the risk of malignancy. Thymectomy frequently  lessens the severity of the MG weakness  after some  months.  In some  people, the weakness  may completely  disappear. This is called a remission. The degree to which the thymectomy  helps varies with each patient.

Plasmapheresis,   or  plasma  exchange,  may  be  useful  in  the  treatment   of  MG  also.  This procedure removes the abnormal antibodies from the plasma of the blood. The improvement in muscle strength may be striking,but is usually short-lived, since production of the abnormal antibodies continues. When plasmapheresis is used, it may require repeated exchanges. Plasma exchange may be especially useful during severe MG weakness or prior to surgery.

Treatment decisions are based on knowledge of the natural history of MG in each patient and the predicted response to a specific form of therapy. Treatment goals are individualized according to the severity of the MG weakness, the patient’s age and sex, and the degree of impairment.

Years Long Jounery
Patients Treated
Mobile Plasmapheresis Centres

24 hours service

PMWO provide 24 hours fast and speedy mobile plasmapheresis service for the clinical management of critical patients with GBS and Myasthenia Gravis

Low Cost Treatment

PMWO solved medicines problem permanently and manufactured world’s cheapest medicine in Pakistan for MG patients.

Growing Network

develop contacts with MG and GBS/CIDP organizations abroad to share information, views and experiences to discover the cure of MG

Free Medication

PMWO has established a National Myasthenic Drug Bank for the distribution of Medicines, to poor patients of Myasthenia Gravis and GBS

Help us in saving priceless lives 
DONATE    Save A Life

Let’s take the next step and work together